A patient with chronic heart failure is admitted with symptoms of fluid overload. The patient has bilateral crackles, jugular venous distention, and +2 pitting edema. The B-type Natriuretic Peptide (BNP) is elevated. The nurse plans to administer furosemide as prescribed. Which of the following assessments should the nurse prioritize before administering the medication?

A) Assess the patient's blood pressure

B) Evaluate the patient's lung sounds

C) Measure the patient's urine output

D) Review the patient's potassium levels

A patient with heart failure presents with bilateral crackles, jugular venous distention, and +2 pitting edema. Their BNP level is 760 pg/mL and ejection fraction is 35%. Considering these findings, which of the following is the most appropriate nursing intervention to prioritize in their care plan?

B) Administer prescribed furosemide to reduce fluid overload.

A) Encourage increased fluid intake to support renal function.

B) Administer prescribed furosemide to reduce fluid overload.

C) Advise the patient to perform daily weight checks without adjusting other treatments.

D) Suggest the patient engage in vigorous exercise to improve cardiac output.

A patient receiving increased doses of furosemide for fluid management shows improvement in edema and pulmonary congestion but presents with hypokalemia and elevated creatinine levels. Which nursing intervention is most appropriate to address the patient's current condition while minimizing further renal strain?

B) Administer potassium supplements and encourage high-potassium foods to address the hypokalemia.

A) Increase the furosemide dose to enhance diuresis and more effectively manage pulmonary congestion.

B) Administer potassium supplements and encourage high-potassium foods to address the hypokalemia.

C) Restrict fluid intake to prevent fluid overload and protect renal function.

D) Initiate an ACE inhibitor to provide renal protection and reduce cardiac workload, despite current hypotension.

A patient undergoing treatment with furosemide for fluid overload shows signs of effective diuresis but now presents with hypokalemia and worsening renal function. Which nursing intervention is most appropriate to implement to address these issues while continuing to manage the patient's cardiac workload?

B) Administer potassium supplements and monitor renal function closely.

A) Increase the furosemide dosage to enhance diuresis.

B) Administer potassium supplements and monitor renal function closely.

C) Initiate a fluid restriction to prevent further fluid overload.

D) Discontinue furosemide and start an ACE inhibitor immediately.

A patient with heart failure and a left ventricular ejection fraction (LVEF) of 35% is started on lisinopril. Which assessment finding would require the nurse to contact the healthcare provider immediately?

B) Serum potassium level of 5.8 mEq/L

A) Blood pressure of 110/70 mmHg

B) Serum potassium level of 5.8 mEq/L

D) BNP level decreased to 400 pg/mL

A patient with heart failure has been initiated on lisinopril, an ACE inhibitor, to improve cardiac output. The nurse is assessing the patient for potential side effects. Which of the following findings should the nurse prioritize for immediate follow-up?

C) Serum potassium level of 5.8 mEq/L

B) Blood pressure reading of 100/60 mmHg

C) Serum potassium level of 5.8 mEq/L

D) Mild dizziness when standing

A patient with heart failure has been on lisinopril therapy and reports dizziness upon standing. The clinical team observes a blood pressure drop from 110/68 mmHg sitting to 90/60 mmHg standing. The patient's potassium level is 3.4 mEq/L, and BNP is 520 pg/mL. What is the most appropriate nursing intervention to prioritize?

B) Instruct the patient to increase intake of potassium-rich foods.

A) Encourage the patient to stand up quickly to build tolerance.

B) Instruct the patient to increase intake of potassium-rich foods.

C) Advise the patient to restrict fluid intake to manage heart failure symptoms.

D) Recommend the use of compression stockings to improve orthostatic tolerance.

A patient with heart failure is experiencing orthostatic hypotension after starting lisinopril therapy. The healthcare team has adjusted the lisinopril dosage and educated the patient on managing symptoms. Concurrently, the patient presents with a slightly low potassium level. What is the nurse's priority action in managing this patient's care?

B) Educate the patient on incorporating more potassium-rich foods into their diet.

A) Advise the patient to increase their fluid intake significantly to counteract dizziness.

B) Educate the patient on incorporating more potassium-rich foods into their diet.

C) Suggest the patient avoid all physical activities until blood pressure stabilizes.

D) Recommend the patient to take an over-the-counter potassium supplement without consulting the healthcare provider.

A patient with systolic heart failure has been experiencing new onset mild shortness of breath and fatigue despite being on lisinopril and diuretic therapy. The healthcare team plans to introduce carvedilol to address these symptoms. Which nursing action is the most appropriate to prioritize when initiating carvedilol therapy?

C) Monitor the patient's blood pressure and heart rate closely, especially for bradycardia and hypotension.

A) Educate the patient about potential side effects of carvedilol, such as dizziness and weight gain.

B) Schedule a follow-up echocardiogram to monitor changes in ejection fraction after starting carvedilol.

C) Monitor the patient's blood pressure and heart rate closely, especially for bradycardia and hypotension.

D) Advise the patient to immediately report any sensation of palpitations or increased heart rate.

A patient with a history of systolic heart failure and recent adjustment in lisinopril dosage now presents with mild shortness of breath, an increased heart rate, and faint crackles upon lung auscultation. The clinical team is considering starting carvedilol. What is the most important nursing intervention to implement before initiating beta-blocker therapy in this patient?

B) Assess the patient's current fluid status, including monitoring daily weights and checking for peripheral edema.

A) Educate the patient on the potential side effects of carvedilol, such as dizziness and fatigue.

B) Assess the patient's current fluid status, including monitoring daily weights and checking for peripheral edema.

C) Ensure the patient can perform a self-check of blood pressure at home to monitor for hypotension.

D) Obtain a baseline electrocardiogram (ECG) to evaluate the patient's cardiac rhythm before starting treatment.

Heart Failure - Nursing Case Study

Pathophysiology

• Primary mechanism: Decreased cardiac output - Heart failure occurs when the heart cannot pump enough blood to meet the body's needs. This reduction in cardiac output triggers compensatory mechanisms that initially help but eventually worsen heart function.

• Secondary mechanism: Neurohormonal activation - To compensate for low cardiac output, the body activates the sympathetic nervous system and renin-angiotensin-aldosterone system, increasing heart rate and blood volume. Over time, these changes lead to fluid overload, increased afterload, and further cardiac deterioration.

• Key complication: Ventricular remodeling - The heart muscle changes shape and size in response to chronic stress, impairing its ability to contract effectively. This remodeling exacerbates heart failure symptoms, such as fluid retention and reduced exercise tolerance.

Patient Profile

Demographics:

65-year-old female, retired school teacher

History:

• Key past medical history: Hypertension, Type 2 Diabetes, Chronic Kidney Disease Stage 2

• Current medications: Lisinopril, Metformin, Furosemide, Aspirin

• Allergies: Penicillin

Current Presentation:

• Chief complaint: Shortness of breath and increased fatigue

• Key symptoms: Orthopnea, paroxysmal nocturnal dyspnea, swelling in legs, reduced exercise tolerance

• Vital signs: Blood pressure 150/95 mmHg, Heart rate 105 bpm, Respiratory rate 24 breaths per minute, Oxygen saturation 92% on room air, Temperature 98.6°F

Section 1

As the clinical team proceeds with the initial assessment, they note significant findings that correlate with the patient's heart failure diagnosis. On auscultation, bilateral crackles are present in the lung bases, indicating pulmonary congestion. Jugular venous distention is visible, suggesting elevated central venous pressure. The patient's lower extremities exhibit pitting edema, graded at +2, suggestive of fluid overload. These findings are consistent with the compensatory mechanisms of heart failure, where the body's attempt to maintain perfusion inadvertently leads to fluid retention and congestion.

The team orders a series of diagnostic tests to further assess the patient's condition. The B-type Natriuretic Peptide (BNP) level returns elevated at 760 pg/mL, a biomarker indicative of heart failure exacerbation. An echocardiogram reveals an ejection fraction of 35%, confirming systolic dysfunction and providing insight into the severity of the ventricular remodeling. Blood tests show a slight worsening of renal function, with a serum creatinine level of 1.8 mg/dL and an estimated glomerular filtration rate (eGFR) of 55 mL/min/1.73 m², reflecting the impact of fluid overload and reduced cardiac output on renal perfusion.

In response to these findings, clinical reasoning leads the team to adjust the patient's management plan. The priority is to alleviate symptoms and prevent further complications. The furosemide dosage is increased to promote diuresis and reduce fluid overload, while careful monitoring of renal function is emphasized due to the patient's chronic kidney disease. Additionally, the team discusses the potential introduction of a beta-blocker to help control the heart rate and further reduce the heart's workload. Regular follow-up and reassessment are planned to evaluate the effectiveness of these interventions and adjust the treatment plan accordingly. This proactive approach aims to stabilize the patient's condition and prevent further deterioration, setting the stage for potential lifestyle modifications and long-term management strategies.

Section 2

As the patient progresses under the current management plan, the clinical team closely monitors for both response to interventions and potential new complications. Within 48 hours of increasing the furosemide dosage, the patient shows signs of effective diuresis, with a net fluid loss of 1.5 liters. The pitting edema in the lower extremities decreases to +1, and the patient's weight is reduced by 3 kg, indicating a positive response to the diuretic therapy. Breath sounds improve, with crackles now only audible at the lung bases, suggesting a reduction in pulmonary congestion. Despite these improvements, the patient's blood pressure is noted to be lower, averaging 100/60 mmHg, which prompts a reevaluation of the medication regimen to ensure adequate perfusion without exacerbating renal function decline.

However, new lab results reveal an emerging complication. The serum potassium level drops to 3.2 mEq/L, likely due to the increased diuresis from furosemide, necessitating immediate intervention to prevent hypokalemia-related complications such as arrhythmias. The team promptly initiates potassium supplementation and reassesses dietary intake to ensure adequate potassium levels. Concurrently, the serum creatinine level shows a slight increase to 2.0 mg/dL, and the eGFR decreases further to 50 mL/min/1.73 m², indicating a strain on renal function despite the diuretic therapy. This finding underscores the importance of striking a balance between fluid management and renal protection.

The clinical team decides to implement a more comprehensive monitoring strategy, including frequent electrolyte checks and renal function assessments. They also consider introducing an ACE inhibitor, which could provide renal protection and further aid in reducing cardiac workload. This decision requires careful titration and monitoring to avoid hypotension and further renal compromise. The patient's care plan is adjusted accordingly, with a focus on maintaining electrolyte balance, optimizing cardiac function, and protecting renal health. This proactive approach aims to stabilize the patient's condition while preparing for potential long-term management strategies, such as lifestyle modifications and cardiac rehabilitation, to improve overall quality of life.

Section 3

As the clinical team continues to monitor the patient, new diagnostic results emerge that provide further insight into the patient's condition. A follow-up echocardiogram reveals a left ventricular ejection fraction (LVEF) of 35%, confirming systolic dysfunction, which is consistent with the patient's heart failure diagnosis. This finding reinforces the need for optimizing heart failure management and justifies the potential introduction of an ACE inhibitor to improve cardiac output and reduce ventricular remodeling. Moreover, a BNP (B-type Natriuretic Peptide) level is checked and noted to be elevated at 550 pg/mL, indicating persistent cardiac stress despite initial improvements in symptoms. This prompts the team to evaluate the overall therapeutic regimen and consider adjustments that could further alleviate cardiac strain.

In light of these diagnostic results, the team decides to cautiously introduce lisinopril, an ACE inhibitor, at a low dose, while vigilantly monitoring the patient's blood pressure and renal function. The goal is to achieve a delicate balance between enhancing cardiac performance and preventing hypotension or further renal impairment. Additionally, dietary modifications and patient education are emphasized to address the patient's ongoing hypokalemia and support long-term adherence to heart failure management protocols. The patient is encouraged to consume potassium-rich foods and to continue with the prescribed potassium supplements as part of a comprehensive plan to stabilize electrolyte levels.

As the patient progresses with these interventions, the clinical team remains attentive to the risk of new complications. They consider the potential for orthostatic hypotension, especially given the patient's borderline low blood pressure. Regular standing blood pressure measurements are introduced to detect any significant drops that could increase fall risk. The team also schedules a follow-up renal panel and electrolyte check within the next 48 hours to ensure that the adjustments in medication and dietary intake are effectively mitigating the risks of renal function decline and electrolyte imbalance. This vigilant monitoring and proactive management aim to support sustained patient improvement and prepare for the next steps in the patient's heart failure care journey.

Section 4

As the patient continues under close observation, the clinical team notes a change in the patient's status. Two days after initiating lisinopril therapy, the patient reports experiencing occasional dizziness upon standing, a possible sign of orthostatic hypotension. Vital signs reveal a blood pressure of 110/68 mmHg while sitting and a drop to 90/60 mmHg upon standing. Though the systolic blood pressure decline is moderate, it prompts the team to consider further adjustments to the patient's medication regimen. The team decides to temporarily reduce the lisinopril dosage and educate the patient on strategies to manage symptoms, such as rising slowly from a seated or lying position and increasing fluid intake within dietary restrictions.

Concurrently, the follow-up renal panel and electrolyte check reveal stable renal function, with a creatinine level holding steady at 1.1 mg/dL. However, the potassium level remains slightly low at 3.4 mEq/L. This reinforces the need for ongoing dietary modifications and adherence to potassium supplementation. The patient is encouraged to continue incorporating potassium-rich foods such as bananas, spinach, and sweet potatoes into their meals, while the team assesses the potential need for an adjusted supplementation strategy.

Despite these developments, the patient's BNP level remains elevated at 520 pg/mL, suggesting ongoing cardiac stress. The clinical team deliberates the possibility of introducing additional pharmacological agents, such as a beta-blocker, to further optimize cardiac output and achieve better symptom control. However, they remain cautious of potential side effects and interactions, particularly given the patient's current challenges with blood pressure. The team plans a collaborative discussion with the patient regarding these options and the importance of continued monitoring, recognizing that a careful balance is required to improve the patient's heart failure management without compromising safety.

Section 5

Two days after adjusting the lisinopril dosage and implementing strategies to manage orthostatic hypotension, the patient reports feeling less dizzy upon standing. However, during a routine assessment, the nurse notices the patient exhibiting mild shortness of breath during conversation, which was not present during previous interactions. Vital signs show a new resting heart rate of 98 beats per minute, up from 86, and a respiratory rate of 22 breaths per minute. Blood pressure is stable at 112/70 mmHg while sitting, but the patient now appears slightly more fatigued, which prompts further evaluation.

An echocardiogram is ordered to reassess the patient's cardiac function, revealing a left ventricular ejection fraction of 35%, unchanged from prior measurements but indicating persistent systolic dysfunction. The lung auscultation identifies faint crackles at the bases, suggesting possible fluid retention despite the patient's adherence to diuretic therapy. These findings raise concern for worsening heart failure symptoms and necessitate a review of the current fluid management and diuretic regimen.

The clinical team considers the introduction of a beta-blocker, specifically carvedilol, at a low dose to improve heart rate control and reduce cardiac workload. They discuss the potential benefits and risks with the patient, emphasizing the need for gradual titration and close monitoring given the recent issues with blood pressure and dizziness. The patient is also reminded about the importance of daily weight monitoring and reporting any sudden changes, as well as adhering to dietary recommendations to help manage fluid status. This careful titration and monitoring aim to address the new symptoms while minimizing the risk of exacerbating the patient's orthostatic hypotension.